Drug Safety Concerns Create CRO Opportunity, PPD Says
This article was originally published in The Pink Sheet Daily
Contract research organizations could see financial opportunities in "more intricate safety monitoring," CEO Eshelman says during earnings call. Regulatory uncertainty accompanies shift in PPD's business away from big pharma, toward biotech firms.
You may also be interested in...
Takeda completes acquisition of development and marketing rights to PPD’s dipeptidyl peptidase IV inhibitors for treatment of type 2 diabetes. PPD will provide clinical development services. The deal follows the discontinuation of Takeda’s in-house novel diabetes agent due to liver abnormalities.
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.